Juan José de la Cruz López

Prof. Juan José de la Cruz López

División Académica de Ciencias Básicas, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
Juan José de la Cruz LópezJuan José de la Cruz López
Juan José de la Cruz López
LVLiliana Villanueva-Lizama
Liliana Villanueva-Lizama
VDVictor Dzul-Huchim
Victor Dzul-Huchim
MRMaría-Jesus Ramírez-Sierra
María-Jesus Ramírez-Sierra
PMPedro Martinez-Vega
Pedro Martinez-Vega
Eric DumonteilEric Dumonteil
Eric Dumonteil
A therapeutic vaccine for human Chagas disease (American trypanosomiasis caused by Trypanosoma cruzi) is under development based on the success of vaccinating mice with DNA constructs expressing the antigens Tc24 and Tc-TSA-1. However, because DNA and nucleic acid vaccines produce less than optimal responses in humans, our strategy relies on administering a recombinant protein-based vaccine, together with adjuvants that promote Th1-type immunity. Here we describe a process for the purification and refolding of recombinant TSA-1 expressed in Escherichia coli. The overall yield (20–25%) and endotoxin level of the purified recombinant TSA-1 (rTSA-1) is suitable for pilot scale production of the antigen for use in phase 1 clinical trials. Mice infected with T. cruzi were treated with rTSA-1, either alone or with Toll-like receptor 4 (TLR-4) agonist adjuvants including monophosphoryl lipid A (MPLA), glucopyranosyl lipid A (GLA, IDRI), and E6020 (EISEI, Inc). TSA-1 with the TLR-4 agonists was effective at reducing parasitemia relative to rTSA-1 alone, although it was difficult to discern a therapeutic effect compared to treatment with TLR-4 agonists alone. However, rTSA-1 with a 10 ug dose of MPLA optimized reductions in cardiac tissue inflammation, which were significantly reduced compared to MPLA alone. It also elicited the lowest parasite burden and the highest levels of TSA-1-specific IFN-gamma levels and IFN-gamma/IL-4 ratios. These results warrant the further evaluation of rTSA-1 in combination with rTc24 in order to maximize the therapeutic effect of vaccine-linked chemotherapy in both mice and non-human primates before advancing to clinical development.

31 May 2013 in Colombia Medica
Verified
Journal Article
Open access
PDF file
GVGuillermo Valencia
Guillermo Valencia
FPFrancisco Javier Pinzon
Francisco Javier Pinzon
Juan José de la Cruz LópezJuan José de la Cruz López
Juan José de la Cruz López
LVLigia del Carmen Vera
Ligia del Carmen Vera
NPNorma Pavia
Norma Pavia
FPFernando Puerto
Fernando Puerto
Introduction: TLR´s play a role in host defense in HIV infection recognizing the viral DNA or RNA. Their activation induces a signaling pathway that includes the proteins MyD88, IRAK4, TRAF6 and the transcription factor NF-kBp65. Objective: To determine the expression of TLR7, TLR8 and TLR9, and activation of its signaling pathway in monocytes from patients infected with HIV. Methods. Expression of TLR7, TLR8 and TLR9 was determined in monocytes from HIV-infected patients (n = 13) and control subjects (n = 13), which were activated with specific ligands. The expression of MyD88 and NF-kBp65 were determined by flow cytometry; IRAK4 and TRAF6 were studied by immunoblotting. Results: No statistical difference was found in the expression of TLR7, 8 and 9 in monocytes from patients compared to controls, but we observed the non-significant increased expression of TLR9 in patients. The activation showed no significant difference in the expression of MyD88 and NF-kBp65 in patients when compared to controls, but were decreased in stimulated cells over non-stimulated cells. IRAK4 and TRAF6 were not detected. Conclusions: No statistical difference was observed in the expression of intracellular TLRs, MyD88 and NFkBp65 in monocytes from patients compared to controls. This was probably due to effective antiretroviral therapy being received at the time of study entry. Additional studies are needed (ARTV) under controlled conditions that include infected patients with and without ARVT, responders and non- responders, and work with different cell populations.

Verified
Journal Article
Open access
PDF file
Juan José de la Cruz LópezJuan José de la Cruz López
Juan José de la Cruz López
Luis Ramón Tercero Martínez GonzálezLuis Ramón Tercero Martínez González
Luis Ramón Tercero Martínez González
CMCecilia Albortante Morato
Cecilia Albortante Morato
RPRosaura Palma-Orozco
Rosaura Palma-Orozco
TFTERESA FLORES
TERESA FLORES
JRJorge Rosas-Trigueros
Jorge Rosas-Trigueros
The ATP-binding cassette transporter A1 (ABCA1) functional variant R230C (rs9282541) is associated with low plasma HDL-C levels, yet its atomic-scale mechanism remains unclear. We evaluated the structural and dynamic impact of R230C compared to wild-type (WT) ABCA1 using 200 ns molecular dynamics simulations in a lipid raft membrane. While the tertiary fold was preserved, R230C exhibited reduced overall flexibility (lower RMSD and localized RMSF rigidification) alongside a slightly expanded conformation (increased Rg and SASA). Localized fluctuations near residue 230 in extracellular domain 1 (ECD1) were coupled with decreased dynamic heterogeneity in distal functional regions, particularly nucleotide-binding domain 2 (NBD2) and transmembrane domain 2 (TMD2). MOSAICS analysis revealed subtle alterations in membrane thickness, midplane displacement, and lipid orientation. Furthermore, CAVER tunnel analysis demonstrated increased pathway heterogeneity (17 clusters in R230C vs. 10 in WT), lower persistence, and smaller bottleneck radii, disrupting the primary cholesterol transport route. Thus, R230C acts as a dynamic allosteric modulator and membrane-coupling agent rather than a folding-disruptive mutation, providing a biophysical rationale for reduced cholesterol efflux and low plasma HDL-C levels.
1